Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

17 Aug 2020

Abstract excerpt

Since the beginning of this century, humanity has been struck three times by the coronavirus outbreak. The most recent one is caused by the SARS-CoV-2 virus, which was first reported in January 2020 and spread rapidly worldwide, developing into a global coronavirus disease pandemic coded COVID-19. 1 By July 28, 2020, SARS-CoV-2 has caused over sixteen million COVID-19 cases worldwide and 650,805 deaths. 2 Such a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32801356
DOI: 10.1038/s41422-020-00392-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in micePMID 32801356Read ↗

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-BSemantic proximity Read ↗

Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19Semantic proximity Read ↗

Perspectives on RNA Vaccine Candidates for COVID-19Semantic proximity Read ↗

COVID-19 Vaccines: Where Do We Stand at the End of 2023?Semantic proximity Read ↗

Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic InterventionsSemantic proximity Read ↗

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic StrategiesSemantic proximity Read ↗

COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.Semantic proximity Read ↗

Essential Considerations During Vaccine Design against COVID-19 and Review of Pioneering Vaccine Candidate PlatformsSemantic proximity Read ↗

Vaccines against COVID-19: Priority to mRNA-Based FormulationsSemantic proximity Read ↗

mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variantsSemantic proximity Read ↗

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and HumansSemantic proximity Read ↗

Vaccines platforms and COVID-19: what you need to knowSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.